Product Description
9MW2921 is a next generation Antibody-Drug Conjugate (ADC) developed by Mabwell based on IDDCâ"¢ (Interchain-Disulfide Drug Conjugate) platform for the treatment of solid tumors. It is an innovative antibody molecule linked to a novel payload (TOP1i) by a novel linker with fully autonomous intellectual property right. When 9MW2921 enters into the body, it can specifically bind to antigens on the cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug and induce the apoptosis of tumor cells. (Sourced from: https://www.mabwell.com/en/news_info/id-93.html)
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mabwell Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 9MW2921-2023-CP101 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2026-09-01 |
42% |
2024-11-22 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/23/2025 |
News Article |
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting |
|
04/24/2025 |
News Article |
Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO |
|
07/16/2024 |
News Article |
FDA Grants Orphan Drug Designation to 7MW3711 |
|
03/21/2024 |
News Article |
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London |